HPC Offered for PRESERVE Expansion

Ossium Health, Inc.10 enrolled

Overview

Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

Study Type

OBSERVATIONAL

Enrollment

Conditions

Bone Marrow Transplant (BMT)

Interventions

Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)OTHER

The HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.

Eligibility

Sex: ALLMin age: 12 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients aged 12-80 may be eligible\* to receive bone marrow for transplantation through the Ossium HOPE Program if: Their treating physician determined they are eligible for allogeneic bone marrow transplant Their treating physician determined that the potential benefit outweighs the potential risks

Locations (4)

University of Alabama, Birmingham

Birmingham, Alabama, United States

RECRUITING

Henry Ford Health

Detroit, Michigan, United States

RECRUITING

The Ohio State University Medical Center

Columbus, Ohio, United States

RECRUITING

Outcomes

Primary Outcomes

Neutrophil engraftment

1\. To determine cumulative incidences of neutrophil engraftment (ANC ≥500/µL for 3 consecutive values)

Time frame: 28 days

Central Contacts

Preethi Prasad, Senior Director Clinical Operations

CONTACT

415-513-5535 preethi.prasad@ossiumhealth.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.